Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jid.2017.01.037 | DOI Listing |
Glob Health Res Policy
January 2025
Department of Global Health, School of Public Health, Peking University, Beijing, China.
Utilizing innovative methods to advance the research and development (R&D) of health products and enhance their accessibility has become crucial to achieving universal health coverage, addressing public health emergencies, and promoting population health and wellbeing. However, structural contradictions do exist in the supply and demand of health products in the Association of Southeast Asian Nations (ASEAN). With the joint support of the Ministry of Science and Technology of China, the Ministry of Education, and the China-ASEAN Center, Peking University established the China-ASEAN Science and Technology Cooperation Center for Public Health in April 2023.
View Article and Find Full Text PDFSci Rep
January 2025
Intensive Care Medicine, Heyou Hospital, Foshan, 528306, Guangdong, China.
Heart failure with preserved ejection fraction (HFpEF) emerges as a singular subclass of heart failure, bereft of specific therapeutic options. Magnesium, an indispensable trace element, is essential to the preservation of cardiac integrity. However, the association between magnesium supplementation and mortality in HFpEF patients remains unclear.
View Article and Find Full Text PDFBlood Cancer J
January 2025
School of Medicine, Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Fedratinib is a predominantly JAK2 inhibitor that has shown efficacy in untreated and ruxolitinib-exposed patients with myelofibrosis (MF). Based on randomized clinical trial data, it is approved for use in patients with International Prognostic Scoring System (IPSS) or Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 or high-risk disease and is distinguished from ruxolitinib in that it can be administered without dose reduction in patients with thrombocytopenia, to a platelet count above 50,000/µL. In these trials, fedratinib achieved significant spleen volume reduction in ~30-45% of patients and improvement in total symptom scores in 35-40% with good tolerability.
View Article and Find Full Text PDFCell Death Dis
January 2025
Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Mitochondrial oxidative phosphorylation (OXPHOS) is a therapeutic vulnerability in glycolysis-deficient cancers. Here we show that inhibiting OXPHOS similarly suppresses the proliferation and tumorigenicity of glycolytically competent colorectal cancer (CRC) cells in vitro and in patient-derived CRC xenografts. While the increased glycolytic activity rapidly replenished the ATP pool, it did not restore the reduced production of aspartate upon OXPHOS inhibition.
View Article and Find Full Text PDFMedicine (Baltimore)
November 2024
Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
The aim of this study is to conduct a comprehensive bibliometric analysis of CT-based adipose tissue imaging related to coronary artery disease (CAD) to investigate the dynamic development of this field. Web of Science Core Collection was used as our data source to identify relevant documents limited to articles or review articles and written in English with no time restrictions. Then we analyzed the whole trend of publications and utilized VOSviewer and Bibliometrix to conduct a bibliometric analysis including citations, keywords, countries, institutions, authors as well as co-citation analyses of cited references and sources.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!